MARKET

XFOR

XFOR

X4 Pharmaceuticals Inc
NASDAQ
3.725
-0.025
-0.67%
After Hours: 3.849 +0.124 +3.32% 19:40 05/02 EDT
OPEN
3.850
PREV CLOSE
3.750
HIGH
3.859
LOW
3.620
VOLUME
201.99K
TURNOVER
--
52 WEEK HIGH
37.50
52 WEEK LOW
3.620
MARKET CAP
21.56M
P/E (TTM)
-0.6665
1D
5D
1M
3M
1Y
5Y
1D
X4 Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters · 1d ago
X4 Pharmaceuticals Price Target Raised to $7.00/Share From $1.50 by HC Wainwright & Co.
Dow Jones · 1d ago
X4 Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Raises Price Target to $7
Benzinga · 1d ago
Cantor Fitzgerald Sticks to Its Buy Rating for X4 Pharmaceuticals (XFOR)
TipRanks · 1d ago
X4 Pharmaceuticals price target raised to $7 from $1.50 at H.C. Wainwright
TipRanks · 1d ago
X4 Pharmaceuticals Reports Positive Q1 2025 Results
TipRanks · 1d ago
X4 Pharmaceuticals’ Earnings Call: Progress Amid Challenges
TipRanks · 2d ago
More
About XFOR
More
X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. It has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
Recently
Symbol
Price
%Change

Webull offers X4 Pharmaceuticals Inc stock information, including NASDAQ: XFOR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XFOR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XFOR stock methods without spending real money on the virtual paper trading platform.